Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
about
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy.Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency
P2860
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@ast
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@en
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@nl
type
label
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@ast
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@en
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@nl
prefLabel
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@ast
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@en
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@nl
P2093
P2860
P1476
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
@en
P2093
Asaad Trabolsi
Ayman Layka
David B. Thomas
Jose Lutzky
Julia Escandon
Stephanie Peacock
P2860
P2888
P356
10.1186/S40425-016-0205-2
P577
2017-01-17T00:00:00Z
P6179
1047104055